Trial Profile
Effect of Cladribine personalised dosing in Multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results of (n=2) people with progressive multiple sclerosis (pwPMS) when treated with cladribine effectively reduced NfL levels, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.